Jennerex Biotherapeutics
San Francisco
About Jennerex Biotherapeutics
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer and colorectal cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $56.1M
- Funding stage: M&A
- Last round: Private Equity (May 2013)
- Website: jennerex.com
- Phone: 14155982600
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/jennerex-biotherapeutics-3693043 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.